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The mission of Psychotherapy and Psychosomatics (to 
be the home of innovative, critical thinking at the inter-
face of behavioral and medical sciences) appears to be 
more timely than ever. The past year offered two notable 
examples of this role.
The expulsion of Peter Gotzsche from the Cochrane, 
an international network of scientists that surveys the lit-
erature on treatment and diagnostics to produce consen-
sus reports on their efficacy, has attracted considerable 
attention both in the scientific and lay press [1, 2]. 
Gotzsche, Director of the Nordic Cochrane Center in Co-
penhagen and a leading scientist in the group, was ex-
pelled for his criticism of a review on the HPV vaccine 
and his critical views about the presence of researchers 
with ties with the pharmaceutical industry among the au-
thors of systematic reviews. Four other board members 
resigned in protest [1]. The dangers related to financial 
conflicts of interest were clearly outlined in 2001 in our 
journal [3] and are of particular concern in meta-analyses 
[4]. The inadequate handling of financial conflicts of in-
terest in the Cochrane meta-analysis casts serious doubts 
on the construction of evidence-based medicine [5]. The 
modalities of expulsion of Peter Gotzsche are suggestive 
of a totalitarian characterization of evidence-based medi-
cine, which Feinstein and Horwitz predicted 2 decades 
ago: 
“The laudable goal of making clinical decision based on evi-
dence can be impaired by the restricted quality and scope of what 
is collected as ‘best available evidence.’ The authoritative aura giv-
en to the collection, however, may lead to major abuses that pro-
duce inappropriate guidelines or doctrinaire dogmas for clinical 
practice” [6, p. 529].
During 2018, the difficulties that patients may have in 
discontinuing antidepressant drugs attracted consider-
able attention in the lay press and forced clinical journals 
and scientific organizations to address the problem after 
2 decades of tight censorship [7–9]. Once again, the wide 
spectrum of withdrawal reactions that arise with antide-
pressant drugs, including the occurrence of persistent 
postwithdrawal disorders, were anticipated by this jour-
nal [10–13]. Not only clinicians have been systematically 
taught to minimize and deny the occurrence of such reac-
tions [9]: current diagnostic systems, such as DSM, ap-
pear to be obsolete since they fail to take into account the 
modifications of psychopathology (behavioral toxicity) 
induced by psychotropic drugs [14].
In 2018, we also launched, together with the Journal of 
Clinical Psychopharmacology, an overdue reappraisal of 
the role of benzodiazepines in medical practice [15–17]. 
Benzodiazepines, because of their widespread use and 
their limited cost, were object of a commercial war: the 
dependence potential of benzodiazepines was dramatized 
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and their prescription was hindered in all possible ways, 
despite the clinical value of this class of medications [9]. 
Physicians thus learned that benzodiazepines were bad 
and could cause dependence, whereas antidepressant 
drugs were devoid of such effects (even though their de-
pendence potential is as much or even worse than that of 
benzodiazepines). This was probably the most spectacu-
lar achievement of propaganda in psychiatry [9]. 
The journal continues to seek medical papers charac-
terized by strong methodological and clinical character-
izations. We are not afraid if they run counter widely ac-
cepted paradigms, because we know that this is the only 
way clinical science may progress. We deal with a broad 
range of clinical issues, particularly at an interdisciplinary 
level, related to assessment and treatment, with particular 
reference to psychotherapy [18], clinical pharmacopsy-
chology [14], and clinimetrics [19]. We welcome both 
critical and systematic reviews. Other journals believe in 
the pseudo-objectivity, obtained by increasingly compli-
cated and cumbersome procedures, of systematic reviews 
and meta-analyses, where the presence of an author with 
clinical familiarity with the topic is an optional. Intellec-
tual poverty connotes many of these reviews: a frequent 
conclusion is that the evidence is too limited and further 
studies are needed, as was found to be the case in more 
than half of the Cochrane reviews [20]. The key charac-
teristic of clinical science is its explicit attention to hu-
manness, where observation (outer-viewing), introspec-
tion (inner-viewing), and dialogue (inter-viewing) are the 
basic methodological triad for clinical assessment and for 
making patient data scientific [21, 22]. We pursue the in-
tellectual richness that only clinical practice can yield. 
Clinical judgment is essential also in meta-analyses, and 
we encourage our authors to use it in material selection 
[23]. Indeed, meta-analyses often include highly hetero-
geneous studies and ascribe conflicting results to random 
variability, whereas different outcomes may reflect differ-
ent patient populations, enrollment, and protocol char-
acteristics [23].
Not surprisingly, the journal has reached a top impact 
factor in 2017 (13.12) and continues its growth (Fig. 1). 
The new impact factor places Psychotherapy and Psycho-
somatics as fourth in the Science Citation Index Psychol-
ogy ranking and fifth in the Psychiatry ranking. These 
rankings, however, do not distinguish whether a journal 
is exclusively concerned with review articles (that are 
more likely to be cited) or publishes also original investi-
gations. In the Science Citation Index Psychology rank-
ing, the 3 journals preceding Psychotherapy and Psycho-
somatics are exclusively dedicated to review articles. This 
indicates that Psychotherapy and Psychosomatics is the 
top journal for original investigations in psychology.
Such achievement is the result of several converging 
efforts. We should acknowledge here the perfect synchro-
ny between Karger’s editorial office and the associate ed-
itors; the work of the editorial board and statistical con-
sultants; the help of many external reviewers (listed be-
low), who dedicated their time and efforts to assess and 
improve the quality of submitted manuscripts; the skills 
of Emanuela Offidani and Andrea Sabbatini who pre-
pared the press releases of the published articles; and the 
support of our authors and readers. 
The following experts have supplemented the editorial 
board by reviewing the manuscripts submitted to Psycho-
therapy and Psychosomatics during 2018 and are grate-
fully acknowledged. Both external referees and editorial 
board members have disclosed potential conflicts of in-
terests. The Editor-in-Chief and the Associate Editors 
have no conflicts of interest to declare for 2018.
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Fig. 1. The 10-year impact factor (IF) of 
Psychotherapy and Psychosomatics.
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